Livzon’s New Approval for Endometriosis Treatment
Company Announcements

Livzon’s New Approval for Endometriosis Treatment

Livzon Pharmaceutical Group (HK:1513) has released an update.

Livzon Pharmaceutical Group Inc. has just received approval from the National Medical Products Administration for a new indication of their drug, Triptorelin Acetate Microspheres for Injection, specifically for the treatment of endometriosis. This marks a significant milestone for the company, expanding the potential market for their product and offering a new therapeutic option for individuals suffering from this condition.

For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskLivzon Pharmaceutical Reports Mixed Q3 2024 Financial Results
TipRanks HongKong Auto-Generated NewsdeskLivzon Pharmaceutical Proposes New Non-Executive Director
TipRanks HongKong Auto-Generated NewsdeskLivzon Pharmaceutical Group Plans Key Meeting for 2024
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App